Cover Image
市場調查報告書

中國的Montelukast市場分析

Investigation Report on China's Montelukast Market, 2018-2022

出版商 China Research and Intelligence 商品編碼 296860
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Montelukast市場分析 Investigation Report on China's Montelukast Market, 2018-2022
出版日期: 2018年11月29日 內容資訊: 英文 30 Pages
簡介

中國國內現在氣喘患者有3000萬人,過敏性鼻炎患者有3000∼4000萬人,還有隨著環境污染的惡化,患者數更為增加。Montelukast被認定是最適合的抗氣喘藥之一。從2005年的上市到2010年,國內Montelukast市場以年複合成長率(CAGR)45%的速度急速成長。競爭企業進入以後成長率下降了,不過儘管如此仍維持著年度10%的成長率,抱有巨大的潛在市場。

本報告提供中國的Montelukast市場相關分析、中國國內的產量及醫院用銷售額、價格趨勢(過去5年份)、各企業、各投藥形態的市場佔有率、主要製造商簡介、未來性的市場趨勢預測(今後5年份)等調查,並將其結果為您概述為以下內容。

第1章 Montelukast的相關概念

  • 定義
  • 症狀
  • 全球市場的銷售情形

第2章 中國的Montelukast市場概要

  • 專利現況
  • 主要製造商
  • 市場規模

第3章 Montelukast的銷售額分析

  • 銷售額
  • 銷售量

第4章 主要廠商的市場佔有率分析

  • 市場佔有率(以金額為準)
  • 市場佔有率(以數量為準)

第5章 各劑型的市場規模分析

  • 各劑型的市場佔有率(以金額為準)
  • 各劑型的市場佔有率(以數量為準)

第6章 Montelukast的醫院用標準價格(各企業)

  • Sichuan Xicheng Otsuka Pharmaceutical Co., Ltd.
  • Lunan Better Pharmaceutical Co., Ltd.
  • Merck & Co., Inc. (USA)
  • Merck Shark. Dohme, MSD(UK)

第7章 主要製造商分析

  • Sichuan Xicheng Otsuka Pharmaceutical Co., Ltd.
  • Lunan Better Pharmaceutical Co., Ltd.
  • Merck & Co., Inc. (USA)

第8章 中國的Montelukast市場未來展望

  • 市場規模的預測
  • 市場競爭的預測

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1811351

Description

More than 300 million people in the world are suffering from seasonal asthma of varying degrees. The number is higher in countries with severe environmental pollution and high tobacco consumption. Asthma and allergic rhinitis are common nowadays. Owing to heavy air pollution, the incidences of these diseases are increasing year by year.

Montelukast, developed by MSD, is widely used in the treatment of allergic rhinitis and asthma. As a selective leukotriene D4 receptor antagonist, it selectively binds to the leukotrienes in the airway, blocks the action of allergic mediators, reduces airway inflammation, and makes the airway unobstructed. In 1998, Montelukast sodium tablets (10 mg) and chewable tablets (5 mg) were approved by the FDA and first marketed in the U.S. in the trade name of "Singulair". In 2000 and 2002, Montelukast chewable tablets (4 mg) and granules (4 mg) were approved for sale, mainly for the prevention and long-term treatment of asthma in adults and children aged above 2.

In 1999, MSD's Montelukast chewable tablets (5mg) and tablets (10mg) were approved to enter China in the trade name of "Singulair", followed by Montelukast chewable tablets (4mg) and granules (4mg). In 2006, the generic Montelukast tablets (10mg) and chewable tablets (5mg) by Sichuan Otsuka Pharmaceutical Co., Ltd. were approved to be sold in the trade name of "Bystine". Many other companies in China have also filed applications for generic Montelukast.

According to CRI's market research, from 2005 to 2010, the annual sales value of Montelukast in China grew at a CAGR of more than 40%. As competing products emerged, the growth rate slowed down from 2011 but stays above 10%. In 2017, the market size of Montelukast was about CNY 552 million. The market was dominated by MSD, Lunan Better Pharmaceutical Co., Ltd., and Sichuan Otsuka Pharmaceutical Co., Ltd. Declining in recent years, the market share by sales value of MSD was close to 73%.

According to statistics, there are more than 30 million asthma patients and 300 million to 400 million patients with allergic rhinitis in China. And the numbers will continue to rise with increasingly serious environmental pollution. In China, Montelukast is considered as one of the best anti-asthmatic drugs, which promises huge market potential.

Topics Covered:

  • Situation of respiratory diseases in China
  • Supply and sales of Montelukast in China
  • Prices of Montelukast in China
  • Competition on China's Montelukast market
  • Market share of Montelukast manufacturers in China
  • Prospect of China's Montelukast Market, 2018-2022

Table of Contents

Table of Contents

1 Basic Concept of Montelukast

  • 1.1 Indications for Montelukast
  • 1.2 Development of Montelukast in China
  • 1.3 Government Approval of Montelukast in China

2 Sales of Montelukast in China, 2013-2017

  • 2.1 Sales Value of Montelukast
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Montelukast
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Montelukast by Dosage Form in China, 2013-2017
    • 2.3.1 Tablets
    • 2.3.2 Granules

3 Analysis on Major Montelukast Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Montelukast Manufacturers 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 MSD
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of MSD's Montelukast in China
  • 3.3 Lunan Better Pharmaceutical Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Lunan Better Pharmaceutical Co., Ltd.'s Montelukast in China
  • 3.4 Sichuan Otsuka Pharmaceutical Co., Ltd.
    • 3.4.1 Enterprise Profile
    • 3.4.2 Sales of Sichuan Otsuka Pharmaceutical Co., Ltd.'s Montelukast in China

4 Prices of Montelukast in China, 2017-2018

  • 4.1 MSD (Singulair)
  • 4.2 Lunan Better Pharmaceutical Co., Ltd. (Pingqi)
  • 4.3 Sichuan Otsuka Pharmaceutical Co., Ltd. (Bystine)

5 Prospect of China's Montelukast Market, 2018-2022

  • 5.1 Forecast on Market Size
  • 5.2 Forecast on Market Trend

Selected Charts

  • Chart Governmental Approval of Montelukast in China
  • Chart Sales Value of Montelukast in China, 2013-2017
  • Chart Sales Value of Montelukast in Parts of China, 2013-2017
  • Chart Sales Volume of Montelukast in China, 2013-2017
  • Chart Sales Volume of Montelukast in Parts of China, 2013-2017
  • Chart Sales Value of Montelukast Tablets in China, 2013-2017
  • Chart Sales Value of Montelukast Granules in China, 2013-2017
  • Chart Market Share by Sales Value of Top 3 Montelukast Manufacturers, 2013-2017
  • Chart Market Share by Sales Volume of Top 3 Montelukast Manufacturers, 2013-2017
  • Chart Sales Value of MSD's Montelukast, 2013-2017
  • Chart Sales Volume of MSD's Montelukast, 2013-2017
  • Chart Sales Value of Lunan Better Pharmaceutical Co., Ltd.'s Montelukast, 2013-2017
  • Chart Sales Volume of Lunan Better Pharmaceutical Co., Ltd.'s Montelukast, 2013-2017
  • Chart Sales Value of Sichuan Otsuka Pharmaceutical Co., Ltd.'s Montelukast, 2013-2017
  • Chart Sales Volume of Sichuan Otsuka Pharmaceutical Co., Ltd.'s Montelukast, 2013-2017
  • Chart Prices of MSD's Montelukast in Parts of China, 2017-2018
  • Chart Prices of Lunan Better Pharmaceutical Co., Ltd.'s Montelukast in Parts of China, 2017-2018
  • Chart Prices of Sichuan Otsuka Pharmaceutical Co., Ltd.'s Montelukast in Parts of China, 2017-2018
  • Chart Forecast on Sales Volume of Montelukast in China, 2018-2022
Back to Top